|
Jul 29
|
Telix H1 2025 Results: Investor Webcast Notification
|
|
Jul 22
|
Telix Pharmaceuticals (ASX:TLX) Confirms 2025 Revenue Forecast Between A$770 Million To A$800 Million
|
|
Jul 22
|
MTTI Announces Dr. Danielle Meyrick to Lead Medical Team
|
|
Jul 22
|
Telix Reports $204M Revenue, Up 63% YOY
|
|
Jul 21
|
Exploring Three High Growth Tech Stocks in Australia
|
|
Jul 17
|
Top ASX Growth Stocks With High Insider Ownership In July 2025
|
|
Jul 10
|
Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available
|
|
Jul 9
|
Gozellix Receives Permanent HCPCS Code
|
|
Jun 29
|
Telix Pharmaceuticals (TLX) Announces That US FDA Approves Label Expansion for Illuccix
|
|
Jun 23
|
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
|
|
Jun 22
|
Pro Medicus And 2 Other High Growth Tech Stocks In Australia
|
|
Jun 20
|
Telix Precision Medicine Announces AlFluor Radiochemistry Platform
|
|
Jun 20
|
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
|
|
Jun 18
|
ASX Growth Stocks With High Insider Ownership To Watch
|
|
Jun 4
|
Telix Pharmaceuticals (ASX:TLX) Gains Portugal Approval for Illuccix in Prostate Cancer Detection
|
|
Jun 3
|
Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan
|
|
Jun 3
|
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
|
|
Apr 28
|
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
|
|
Apr 22
|
Telix Reports US$186M Q1 Revenue, Up 62% YOY
|
|
Mar 12
|
Telix Adds Lead-212 Isotope Production Capability
|